Skip to content

Hormonal and Metabolic Consequences of Sleep Disorders in Young Obese Patients

Hormonal and Metabolic Consequences of Sleep Disorders in Young Obese Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00716222
Acronym
SOM
Enrollment
70
Registered
2008-07-16
Start date
2008-05-31
Completion date
2009-05-31
Last updated
2009-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Sleep Disorders

Brief summary

There is a well-documented relationship between short sleep duration and high body mass index (BMI). The mechanism linking short sleep duration and weight gain is unknown. Current studies in healthy young volunteers have shown that experimental sleep restriction is associated with dysregulation of the neuroendocrine control of appetite and with alterations in glucose metabolism. The goal of our study is to determine the metabolic and hormonal modifications induced by chronic sleep curtailment in obese adolescents and young adults and to observe if short sleep is a negative prognostic factor in their weight evolution.

Detailed description

The main purpose of the study is investigate whether the concentrations of 2 hormones that regulate appetite (leptin, ghrelin), cytokines (TNF-a, IL-6) and CRP are modified in obese adolescents and young adults who had sleep disorders in comparison to obese adolescents and young adults who sleep longer.

Interventions

None listed

Sponsors

Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
13 Years to 25 Years
Healthy volunteers
No

Inclusion criteria

* 13-25 years old * BMI \> 30 kg/m2 (If adolescents aged under 18 years: BMI equivalent to a BMI for age and sex to a BMI of 30, according to the Cole et al. obesity criteria).

Exclusion criteria

* Infection * Liver disease * Chronic inflammatory disease * Endocrine disease * Use of drugs that alter the sensitivity of insulin

Countries

Belgium

Contacts

Primary ContactVeronique VB Beauloye, PhD
Veronique.Beauloye@uclouvain.be+3227641370

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026